BABYLAT: A NEW DEVICE TO IMPROVE PRETERM NUTRITION
Our innovative device enriches macronutriental content of human milk onsite
The problem we solve
During the first months of life, a lack of macro-and micronutrients in preterm infant's diet causes growth delay (1). Human milk is the best nutrition for any neonate but for preterm neonates it can not cover their special daily needs in extra protein content. Nowadays to solve this problem the proteins of non-human origin (cow's milk proteins) are added into human milk to increase its protein value. Such fortified milk allows the child to get the necessary amount of nutrients, but this practice also carries a potential risk of side effects due to the non-human origin of the proteins (2). Additionally it prevents to keep 100% human milk-based diet, which is recommended by WHO to any neonate during first six months of live (3). The only way to solve this problem is to add to the human milk the human-milk origin proteins. With our novel device we hope we can provide an innovative solution for this well-known problem.
References:
1. Arslanoglu S, Boquien CY, King C, Lamireau D, Tonetto P, Barnett D, Bertino E, Gaya A, Gebauer C, Grovslien A, Moro GE, Weaver G, Wesolowska AM, Picaud JC. Fortification of Human Milk for Preterm Infants: Update and Recommendations of the European Milk Bank Association (EMBA) Working Group on Human Milk Fortification. Front Pediatr. 2019 Mar 22;7:76.
2. Melinda J. Elliott, Sergio G. Golombek; Evolution of Preterm Infant Nutrition from Breastfeeding to an Exclusive Human Milk Diet: A Review. Neoreviews August 2022; 23 (8): e558–e571.
3. https://www.who.int/health-topics/breastfeeding#ta...
References:
1. Arslanoglu S, Boquien CY, King C, Lamireau D, Tonetto P, Barnett D, Bertino E, Gaya A, Gebauer C, Grovslien A, Moro GE, Weaver G, Wesolowska AM, Picaud JC. Fortification of Human Milk for Preterm Infants: Update and Recommendations of the European Milk Bank Association (EMBA) Working Group on Human Milk Fortification. Front Pediatr. 2019 Mar 22;7:76.
2. Melinda J. Elliott, Sergio G. Golombek; Evolution of Preterm Infant Nutrition from Breastfeeding to an Exclusive Human Milk Diet: A Review. Neoreviews August 2022; 23 (8): e558–e571.
3. https://www.who.int/health-topics/breastfeeding#ta...
What is Babylat?
Babylat is the first automated tabletop device designed to enrich human milk with protein and fat. It is easy to use and does not require specialized medical training, as the enrichment process is fully automated and does not rely on additional laboratory equipment. After processing, the enriched fraction is added back to human milk to increase its protein and energy content without the use of cow’s milk–based products.
Babylat offers a unique solution for feeding preterm infants more effectively with their mother’s own milk or donor milk, by enabling the on-site preparation of HMDF (human-milk-derived fortifier).
Babylat offers a unique solution for feeding preterm infants more effectively with their mother’s own milk or donor milk, by enabling the on-site preparation of HMDF (human-milk-derived fortifier).
Our Benefits
-
TIME FOR ENRICHMENTThe enrichment process takes less than any known market-available solutions
-
No additivesBabylat device uses only human milk with no chemical additives. This feature minimizes the risk to the baby's health -
Product variabilityThe ability to select a unique composition to meet the needs of each individual baby -
On-site enrichmentOur device allows enrichment process to be performed at any interested hospital onsite -
personalized nutritionA unique option to use only mother's milk to create an enriched product -
Low costFewer steps to enrich human milk by our novel method significantly reduce production costs -
Zero-km productNovel fast protocol allows to keep the human milk -origin product to be as natural as possible and has less negative impact to CO2 emission (zero-logistic) -
Ethically non-biasedWe do not commercialize human milk and its derivatives and the origin of the human milk is controlled by health providers
About us
Babylat AG is a Swiss med-tech company founded in 2020 in Bern. We develop bedside device for preterm infants for preparing individualized human-milk-derived fortifier (HMDF) directly in the hospital setting. Babylat has received support from Innosuisse (Swiss Innovation national funding agency) for its project Automated Human Milk Enricher for Nutrition Optimization for Low Weight Preterm Infants (Project no. 62241.1 IP-LS; Innolink: 100.060 IP-LS) and from BAS (Business Angels of Switzerland). Since 01.02.2026, we have also been collaborating with Gdańsk University of Technology and the Medical University of Gdańsk in the Swiss–Polish applied research project “Innovative Technologies for Personalized Human Milk Fortification in Preterm Care: From Industrialization to Clinical Validation” (PreciousHMFstudy).
Meet Our Team
The highly-dedicated team of professionals driven by wish to help to neonates
- Zina Yudina, PhDFounder and CEOExperience:
>15 years of experience with a profound knowledge in molecular biology and biochemistry
Roles:
Research, device development. fundraising, IP, clinicians communications - Henrico DolfingNon-executive member of Board of Directors>20 years of experience as entrepreneur, investor, crisis manager, author of several books
Roles:
Project planning, investor relation, business strategy - Olivia MayerScientific Advisor>20 years of experience in NICU nutrition with deep clinical expertise in neonatal feeding and human milk–based nutrition
Contact details:
If you have any questions – contact us!
E-Mail
info@babylat.com
Address
Babylat AG
Weyermannsstrasse 36
3008 Bern
Switzerland
Weyermannsstrasse 36
3008 Bern
Switzerland
We use cookies to provide the best site experience.
Our partners
We collaborate with a diverse range of organizations to achieve shared goals.
Babylat Device: A Short Demo on How to Use It
News about us
Here we publish most recent news about us
- March 2025Babylat Completed Its First Clinically Ready Prototype Together with Creanova in March 2025
- July 2025Babylat Featured on The Incubator Podcast in July 2025 https://www.the-incubator.org/post/326-babylat-custom-human-milk-fortifiers-from-mother-s-milk
- November 2025We are running survey right now, help us to distribute https://www.surveymonkey.com/r/parents-perspectives-human-milk-fortifiers
- March 2026Media: Founded.ch highlights Babylat’s bedside human milk enrichment approach https://founded.ch/muttermilch-fuer-fruehgeborene/
- April 2026Babylat Receives FDA Breakthrough Device Designation
Babylat AG is pleased to announce that the Babylat Enricher has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA).
FDA Breakthrough Device Designation is granted to technologies that have the potential to provide more effective treatment or diagnosis for life-threatening or irreversibly debilitating conditions where significant unmet medical need exists.
This milestone represents an important validation of Babylat’s mission and supports the company’s next steps toward clinical validation, regulatory development, and future access for fragile preterm infants.
- April 2026PreciousHMFstudy Project Kick-Off Held in Gdańsk
Babylat AG was pleased to participate in the official kick-off meeting of the PreciousHMFstudy project in Gdańsk.
PreciousHMFstudy is a three-year Swiss–Polish collaborative project with total funding of approximately CHF 1.0 million. The project brings together Babylat AG, Gdańsk University of Technology, Medical University of Gdańsk, and PREMS.
The project will support preclinical and clinical validation, as well as further development of the Babylat Enricher and the complementary human milk analyser.
This collaboration marks an important step in Babylat’s mission to make human-milk-derived fortification more accessible for premature infants. - June 2026In June 2026, Babylat held a demo day with Babylat Enricher in Gdańsk together with our Polish project partners. The meeting brought together researchers from Gdańsk University of Technology (GUT) and clinical dietitians from the Medical University of Gdańsk (GUM) to review the Babylat device, discuss the planned research workflow, and align on the next steps for preclinical and clinical preparation. Now, the preclinical stage has officially started.
This was an important milestone for the Swiss–Polish collaboration, supporting the joint development of Babylat’s bedside human milk-derived fortifier technology for vulnerable preterm infants.
